ERBB2 and neoplasm: The pretherapeutic diagnostic evaluation of relapsed metastatic breast cancer includes the revision of the HER2 protein positivity (tumor genetic instability) by a biopsy of metastatic lesions and the identification of PIK3CA genetic mutations as well as the PD-L1 immune receptor [21,22].